"We are surprised by the (U.S. Food & Drug Administration's) feedback, which is a drastic change from the guidance the FDA provided in November 2024," said Matt Kapusta, UniQure's CEO. UniQure said it plans to urgently interact with the FDA to find a path forward for the timely accelerated approval of AMT-130.

---

I would need more time to really look at Google's tax position, but just looking quickly, they had a higher effective tax rate in 2024 than the AMT. So they may not be in the same position as Meta was, who had a lower effective tax rate than the AMT.

---

1 big beautiful AMT tax

---